If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My last update on CRISPR Therapeutics AG (NASDAQ: CRSP ) for Seeking Alpha was posted on July 23rd. It was full of praise for theThe group is for both novice and experienced biotech investors. It provides catalysts ...

新闻订阅服务 - 提供针对生物技术、制药和医疗保健行业股票的每周新闻订阅服务 重点关注行业趋势和估值驱动因素 [1] - 服务内容涵盖催化剂提示 买卖评级 产品销售预测 综合财务报表 贴现现金流分析和分市场分析 [1] - 分析师团队具备超过5年行业研究经验 已完成超过1000家公司的详细研究报告 [1] 分析师持仓披露 - 分析师通过股票、期权或其他衍生工具持有CRISPR Therapeutics AG（CRSP）的多头头寸 [2] 内容免责声明 - 分析内容代表作者个人观点 未获得除Seeking Alpha以外任何形式的补偿 [2] - 分析机构与提及公司不存在业务关系 [2] - 分析作者包含专业投资者和个体投资者 可能未获得任何机构或监管机构的许可或认证 [3]

公司治理更新 - 任命拥有超过50年经验且曾在德勤工作40年的注册会计师W Mark Watson为首席独立董事 [1][2] - 董事会正在采用董事持股政策以强化董事会与股东利益的一致性 [1][3] - 新任首席独立董事强调恢复纳斯达克合规对公司长期成功至关重要 [3] 股东会议与投票事项 - 将于2025年9月19日太平洋时间上午8:30以纯虚拟形式举行特别股东大会 [4] - 鼓励所有在2025年7月29日登记在册的股东于2025年9月18日东部时间23:59前对股票反向分割提案进行投票 [1][5] - 此前投反对票的股东可更改投票支持该提案 [5] 业务与技术平台 - 公司为临床阶段生物技术企业 专注于开发基于专有递送平台的口服重组疫苗 [1][6] - 疫苗平台采用药丸形式 无需冷藏储存运输且避免针头损伤风险 [6] - 研发管线包括针对冠状病毒、诺如病毒、流感的预防性疫苗及治疗HPV的免疫肿瘤疫苗 [6][7] - 已提交覆盖腺病毒和TLR3激动剂口服接种技术的国内外专利申请 [7] 投资者沟通 - 管理层通过季度电话会议和炉边谈话系列与股东保持直接沟通 [3] - 设立专门代理征集机构Campaign Management提供投票协助服务 [5]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?When I last covered Soleno Therapeutics (NASDAQ: SLNO ), it was late March, and the Redwood City, California-based biotech had just announced the approval of its drug Vykat (diazoxide choline) to treat patients aged ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with total revenue for the quarter reaching approximately $101.7 million. This included net product sales of $58.9 million and contract revenues from collaborations of $42.7 million. The company also generated $59.6 million in net income. Following the results, Jefferies analyst Eun Yang maintained a Hold ratin ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is one of the best affordable biotech stocks to invest in now. On September 4, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced positive new data supporting the foundational role of MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM). The new data from pre-specified analysis showed that “patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decli ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best affordable biotech stocks to invest in now. On September 8, BMO Capital analyst Kostas Biliouris reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), retaining a price target of $115.00. BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying The analyst told investors that one of the key reasons supporting the optimistic rating is the potential expansion of Palynziq into the adolescent ma ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15- ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now. The company develops precision genetic medicines using base editing, a next-generation approach that makes single-letter changes in DNA without cutting the double helix. This innovation reduces risks associated with traditional gene editing and offers higher accuracy. Beam’s platform could become the standard for safe and precise genetic corrections, placing it firmly among emerging biotech leaders. On Se ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to buy right now. The company develops next-generation cell and gene therapies, including ex vivo engineered cells and in vivo delivery technologies. Its focus is on creating medicines that can repair or control genes and replace damaged cells. Still in early clinical stages, Sana Biotechnology Inc. (NASDAQ:SANA) represents the frontier of regenerative medicine, with transformative potential but significant development ris ...